Objective:
This study aimed to examine whether DC101 (anti-VEGFR2 antibody)-
modified micelles have applications as novel drug delivery devices, which allow small molecule
antiangiogenic agents to deliver to angiogenic sites on a murine laser-induced choroidal neovascularization
(CNV) model.
Materials and Method:
CNV was induced by photocoagulation on the unilateral eye of each
mouse under anesthesia. Immediately after laser coagulation, E7974-loaded DC101-modified micelles
and motesanib-loaded DC101-modified micelles were intravitreally administrated. Two
weeks after photocoagulation, CNV was visualized using fluorescein-conjugated dextran
(MW=2,000 kDa), and the CNV area was measured in retinal pigment epithelium (RPE)-choroidal
flat mounts.
Results:
Intravitreal administration of both DC101-modified micelles loaded with E7974 at 2 µM
and motesanib at 2 µM significantly reduced CNV area in the murine laser-induced CNV model at
a clearly lower concentration than the effective dose of each agent.
Conclusion:
These results suggest that DC101-modified micelle might be effective drug carrier
system for treating CNV and other ocular angiogenic diseases.
Intravenous route to choroidal neovascularization by macrophage-disguised nanocarriers for mTOR modulation
